Resistance to third-generation cephalosporins in human non-typhoidal Salmonella enterica isolates from England and Wales, 2010-12.

OBJECTIVES To identify the mechanism(s) underlying cefotaxime resistance in 118 of 21,641 (0.55%) non-typhoidal Salmonella enterica isolates collected from humans throughout England and Wales from January 2010 to September 2012. METHODS Non-duplicate isolates (n = 118) resistant to cefotaxime (MICs >1 mg/L) were screened by PCR for genes encoding CTX-M extended-spectrum β-lactamases (ESBLs) and associated ISEcp1-like elements, and for genes encoding acquired AmpC, SHV, TEM, VEB, PER and GES β-lactamases. Sequencing was used to identify specific alleles in selected isolates. Carbapenem resistance was sought by ertapenem disc screening. RESULTS Seventy-nine isolates (0.37% of all referred S. enterica) produced ESBLs, 37 isolates (0.17%) produced CMY-type AmpC enzymes, and 1 isolate had both enzyme types; the mechanism of cefotaxime resistance in 3 isolates could not be identified. Group 1 CTX-M genes were identified in 57 isolates belonging to 22 serotypes, with CTX-M-1 (n = 11), -15 (n = 9) and -55/57 (n = 8) the most prevalent alleles among the 29 (51%) investigated. CTX-M-2 (n = 5), -14 (n = 5), -8 (n = 1) and -65 (n = 1) were also identified. TEM-52 was identified in two isolates and SHV-12 in seven isolates. There was no evidence of carbapenem resistance. ESBL and AmpC genes were detected in both domestically acquired and travel-associated salmonellae. Eighty-nine isolates (75%) were multidrug resistant (resistant to at least three antimicrobial classes) and 42 (36%) had decreased susceptibility to ciprofloxacin (MICs 0.25-1 mg/L), with a further 13 (11%) isolates resistant (MICs >1 mg/L). CONCLUSIONS The prevalence of CTX-M and acquired AmpC genes in human non-typhoidal S. enterica from England and Wales is still low, but has increased from 0.03% in 2001-03 to 0.49% in 2010-12. Resistance to third-generation cephalosporins requires monitoring as it may reduce therapeutic options.

[1]  F. Weill,et al.  Highly drug-resistant Salmonella enterica serotype Kentucky ST198-X1: a microbiological study. , 2013, The Lancet. Infectious diseases.

[2]  H. Hasman,et al.  Public health risks of enterobacterial isolates producing extended-spectrum β-lactamases or AmpC β-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Hasman,et al.  Characterization of IncN plasmids carrying bla CTX-M-1 and qnr genes in Escherichia coli and Salmonella from animals, the environment and humans. , 2013, The Journal of antimicrobial chemotherapy.

[4]  K. Carroll,et al.  First NDM-Positive Salmonella sp. Strain Identified in the United States , 2011, Antimicrobial Agents and Chemotherapy.

[5]  J. Wain,et al.  International spread of an epidemic population of Salmonella enterica serotype Kentucky ST198 resistant to ciprofloxacin. , 2011, The Journal of infectious diseases.

[6]  K. Yuen,et al.  Extensive dissemination of CTX-M-producing Escherichia coli with multidrug resistance to 'critically important' antibiotics among food animals in Hong Kong, 2008-10. , 2011, The Journal of antimicrobial chemotherapy.

[7]  S. Parija,et al.  Molecular characterization of antimicrobial resistance in non-typhoidal salmonellae associated with systemic manifestations from India. , 2010, Journal of medical microbiology.

[8]  A. Brisabois,et al.  IncI1 Plasmid Carrying Extended-Spectrum-β-Lactamase Gene blaCTX-M-1 in Salmonella enterica Isolates from Poultry and Humans in France, 2003 to 2008 , 2010, Antimicrobial Agents and Chemotherapy.

[9]  M. Hayden,et al.  Direct Ertapenem Disk Screening Method for Identification of KPC-Producing Klebsiella pneumoniae and Escherichia coli in Surveillance Swab Specimens , 2010, Journal of Clinical Microbiology.

[10]  S. Herrera-León,et al.  Emergence of extended-spectrum beta-lactamases and AmpC-type beta-lactamases in human Salmonella isolated in Spain from 2001 to 2005. , 2009, The Journal of antimicrobial chemotherapy.

[11]  F. Aarestrup,et al.  Emergence of Multidrug-Resistant Salmonella Concord Infections in Europe and the United States in Children Adopted From Ethiopia, 2003–2007 , 2009, The Pediatric infectious disease journal.

[12]  C. Chiu,et al.  High Rate of Reduced Susceptibility to Ciprofloxacin and Ceftriaxone among Nontyphoid Salmonella Clinical Isolates in Asia , 2009, Antimicrobial Agents and Chemotherapy.

[13]  K. Hopkins,et al.  Plasmid-mediated Quinolone Resistance in Salmonella enterica, United Kingdom , 2008, Emerging infectious diseases.

[14]  Jennifer E. Stevenson,et al.  Human Salmonella and Concurrent Decreased Susceptibility to Quinolones and Extended-Spectrum Cephalosporins , 2007, Emerging infectious diseases.

[15]  F. Weill,et al.  Comparative Analysis of IncHI2 Plasmids Carrying blaCTX-M-2 or blaCTX-M-9 from Escherichia coli and Salmonella enterica Strains Isolated from Poultry and Humans , 2007, Antimicrobial Agents and Chemotherapy.

[16]  A. Apisarnthanarak,et al.  The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum beta-lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. , 2007, Diagnostic microbiology and infectious disease.

[17]  F. Weill,et al.  Dissemination of an Extended-Spectrum-β-Lactamase blaTEM-52 Gene-Carrying IncI1 Plasmid in Various Salmonella enterica Serovars Isolated from Poultry and Humans in Belgium and France between 2001 and 2005 , 2007, Antimicrobial Agents and Chemotherapy.

[18]  F. Weill,et al.  Clonal Emergence of Extended-Spectrum β-Lactamase (CTX-M-2)-Producing Salmonella enterica Serovar Virchow Isolates with Reduced Susceptibilities to Ciprofloxacin among Poultry and Humans in Belgium and France (2000 to 2003) , 2006, Journal of Clinical Microbiology.

[19]  K. Hopkins,et al.  Characterization of AmpC-Mediated Resistance in Clinical Salmonella Isolates Recovered from Humans during the Period 1992 to 2003 in England and Wales , 2005, Journal of Clinical Microbiology.

[20]  K. Hopkins,et al.  blaCTX-M Genes in Clinical Salmonella Isolates Recovered from Humans in England and Wales from 1992 to 2003 , 2005, Antimicrobial Agents and Chemotherapy.

[21]  V. Miriagou,et al.  Expanded-spectrum cephalosporin resistance in non-typhoid Salmonella. , 2004, International journal of antimicrobial agents.

[22]  V. Miriagou,et al.  Imipenem Resistance in a Salmonella Clinical Strain Due to Plasmid-Mediated Class A Carbapenemase KPC-2 , 2003, Antimicrobial Agents and Chemotherapy.

[23]  C. Chiu,et al.  In Vivo Acquisition of Ceftriaxone Resistance in Salmonella enterica Serotype Anatum , 2003, Antimicrobial Agents and Chemotherapy.

[24]  L. Piddock.  Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. , 2002, FEMS microbiology reviews.

[25]  J. Perrier-Gros-Claude,et al.  Dual Emergence in Food and Humans of a Novel Multiresistant Serotype of Salmonella in Senegal: Salmonella enterica subsp. enterica Serotype 35:c:1,2 , 2001, Journal of Clinical Microbiology.

[26]  M. Woodward,et al.  Variation in clonality and antibiotic-resistance genes among multiresistant Salmonella enterica serotype typhimurium phage-type U302 (MR U302) from humans, animals, and foods. , 2001, Microbial drug resistance.